Table of Content

1. Introduction to Natural Killer (NK) Cell Therapy


2. Mechanism of Action of NK Cell Therapy
2.1 Cytotoxic Action of NK Cells
2.2 Working of NK Cell Therapy
2.3 NK Cell Therapies Approaches
2.3.1 CAR NK Cell Therapies
2.3.2 TCR NK Cell Therapies


3. Treatment Strategies For NK Cell Therapies
3.1 NK Cell Therapy As Monotherapy
3.2 NK Cell Therapy As Combinatorial Agent


4. Application of NK Cell Therapy By Indication
4.1 NK Cell Therapy For Cancer
4.2 COVID-19 & Other Viral Infections


5. NK Cell Therapy Characteristics Enhancement Approaches
5.1 Use Of Nanotechnology
5.2 Modifications In CARs
5.3 Use Of CRISPR/Cas9 Gene Editing


6. Global Natural Killer Cell Therapies Clinical Trials Overview
6.1 By Company
6.2 By Country
6.3 By Indication
6.4 By Patient Segment
6.5 By Phase


7. Global Natural Killer Cell Therapies Clinical Trials By Company, Indication & Phase
7.1 Research
7.2 Preclinical
7.3 Phase-I
7.4 Phase-I/II
7.5 Phase-II
7.6 Phase-II/III


8. NK Cell Based Therapy Proprietary Technologies Insight
8.1 Overview
8.2 Proprietary Technologies By Company


9. Partnerships & Funding for NK Cell Therapies
9.1 Recent Partnerships, Collaborations & Licensing Agreements
9.2 Funding Deals By Companies


10. Investigational NK Cell Therapies With FDA Designations
10.1 FDA Fast Track Designation
10.2 FDA Orphan Drug Designation


11. NK Cell Therapies Market Trends & Clinical Trials Outlook
11.1 Current Market Trends, Developments & Clinical Trials Assessment
11.2 Future Commercialization Opportunity


12. Competitive Landscape
12.1 Acepodia
12.2 Beijing JD Biotech
12.3 Cartherics
12.4 Catamaran Bio
12.5 Century Therapeutics
12.6 City of Hope National Medical Center
12.7 CRISPR Therapeutics
12.8 CytoImmune Therapeutics
12.9 Cytovia Therapeutics
12.10 Dragonfly Therapeutics
12.11 Editas Medicine
12.12 Fate Therapeutics
12.13 Gamida-Cell
12.14 GC Biopharma/GC Lab Cell
12.15 GICELL
12.16 Glycostem
12.17 HK inno.N
12.18 ImmunityBio
12.19 Karolinska Institute
12.20 Kiadis Pharma
12.21 Nkarta Therapeutics
12.22 NKGen Biotech
12.23 ONK Therapeutics
12.24 Phio Pharmaceuticals
12.25 Sanofi
12.26 Senti Biosciences
12.27 Shoreline Biosciences
12.28 Sian Wuhan Medical Technology
12.29 Smart Immune
12.30 Sorrento Therapeutics
12.31 Therabest Korea
12.32 University of California
12.33 University Of Minnesota
12.34 University of Texas M. D. Anderson Cancer Center
12.35 XNK Therapeutics
12.36 Zelluna Immunotherapy



List of Figures

Figure 1-1: NK Cells – Identification & Discovery Timeline
Figure 1-2: NK Cell Subsets - CD56low/dim v/s CD56bright

Figure 2-1: Cytotoxic Action Of NK Cells
Figure 2-2: CAR-NK Cells Preparation
Figure 2-3: Delivery Of CAR Gene Into NK Cell
Figure 2-4: NK Cells Sources For Therapy
Figure 2-5: Structure Of CAR/TCR-NK Cell

Figure 4-1: AB-101 Phase 1/2 Study – Initiation & Completion Years
Figure 4-2: SMT-NK Phase 2/3 Study – Initiation & Completion Years
Figure 4-3: CYNK-001 Phase 1 CYNK001AML01 Study – Initiation & Completion Years
Figure 4-4: CYNK-001 Phase 1 Study – Initiation & Completion Years
Figure 4-5: CYNK-101 Phase 1/2 Study – Initiation & Completion Years
Figure 4-6: FT538 Phase 1 Study – Initiation & Completion Years
Figure 4-7: CYNK-001 Phase 1/2 CYNKCOVID Study – Initiation & Completion Years
Figure 4-8: DVX201 Phase 1 Study – Initiation & Completion Years
Figure 4-9: FT538 Phase 1 Study – Initiation & Completion Years

Figure 5-1: Improvements In NK Cell Therapy Using Nanotechnology
Figure 5-2: Basic Structure Of CARs On NK Cell
Figure 5-3: Gene Editing Tools

Figure 6-1: Global – NK Cell Therapies Clinical Trials By Company, 2023 till 2028
Figure 6-2: Global – NK Cell Therapies Clinical Trials By Country, 2023 till 2028
Figure 6-3: Global – NK Cell Therapies Clinical Trials By Indication, 2023 till 2028
Figure 6-4: Global – NK Cell Therapies Clinical Trials By Patient Segment, 2023 till
2028
Figure 6-5: Global – NK Cell Therapies Clinical Trials By Phase, 2023 till 2028

Figure 8-1: Artiva Biotherapeutics - Proprietary CAR-NK Cell Platform
Figure 8-2: Artiva Biotherapeutics - Proprietary AlloNKTM NK Cell Therapy Scaling
Platform
Figure 8-3: Catamaran Bio – Proprietary Tailwind? Platform
Figure 8-4: GAIA BioMedicine - Proprietary NK Cell Therapy Working Mechanism
Figure 8-5: GAIA BioMedicine – Proprietary Technologies’ Salient Features
Figure 8-6: Gamida Cell – NK Cell Therapy Manufacturing Process
Figure 8-7: HebeCell - Proprietary Scalable NK Cell Technology
Figure 8-8: ImmunityBio – Proprietary haNK? Cell Structure
Figure 8-9: Nkarta - Proprietary CAR-NK Cell Structure
Figure 8-10: Nkarta - Proprietary NK Cell Therapy Platform
Figure 8-11: Senti Biosciences - Gene Circuit Technology Platform
Figure 8-12: Senti Biosciences - Gene Circuit Technology Platform Applicability
Figure 8-13: Wugen – Proprietary Memory NK Cell Platform
Figure 8-14: XNK Therapeutics – Autologous NK Cell Therapy Platform